Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

benzhydrocodone

- PMLiVE

New FDA guidance for advertising

Clarifies circumstances when drug names need to be mentioned

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

FDA turns down Forest/Gedeon Richter’s antipsychotic

US regulator wants more information for cariprazine

- PMLiVE

Pfizer extends optimisation campaign

Pharma company supports efforts to ensure public get best out of medicines

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

- PMLiVE

How Pfizer reclaimed its Twitter brand

Company explains how it took back its name on the social network

- PMLiVE

FDA clears J&J’s breakthrough lymphoma therapy

Imbruvica approved to treat mantle cell lymphoma

- PMLiVE

Sarepta slumps as FDA questions muscular dystrophy drug

US regulator casts doubt on biomarker for eteplirsen

Pfizer finally acquires the @pfizer name on Twitter

Will streamline its existing @pfizer_news account

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links